Syndax Pharma (SNDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -285,422 | -217,408 | -156,693 | -84,846 | -318,758 |
| Depreciation Amortization | -10,519 | -8,991 | -6,643 | -3,487 | -13,430 |
| Accounts receivable | -36,830 | -52,800 | -11,846 | -8,120 | -11,237 |
| Accounts payable and accrued liabilities | 4,954 | 2,200 | 5,727 | -1,579 | 1,665 |
| Other Working Capital | -79,318 | -67,560 | -44,181 | -17,475 | 12,807 |
| Other Operating Activity | 84,155 | 91,067 | 30,679 | 20,345 | 54,050 |
| Operating Cash Flow | $-322,980 | $-253,492 | $-182,957 | $-95,162 | $-274,903 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 290,223 | 208,589 | 136,029 | 94,142 | -219,775 |
| PPE Investments | -187 | -131 | N/A | N/A | N/A |
| Investing Cash Flow | $290,036 | $208,458 | $136,029 | $94,142 | $-219,775 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 343,652 |
| Common Stock Issued | 13,676 | 7,759 | 1,481 | 930 | 9,715 |
| Financing Cash Flow | $13,676 | $7,759 | $1,481 | $930 | $353,367 |
| Beginning Cash Position | 154,300 | 154,300 | 154,300 | 154,300 | 295,611 |
| End Cash Position | 135,032 | 117,025 | 108,853 | 154,210 | 154,300 |
| Net Cash Flow | $-19,268 | $-37,275 | $-45,447 | $-90 | $-141,311 |
| Free Cash Flow | |||||
| Operating Cash Flow | -322,980 | -253,492 | -182,957 | -95,162 | -274,903 |
| Capital Expenditure | -187 | -131 | N/A | N/A | N/A |
| Free Cash Flow | -323,167 | -253,623 | -182,957 | -95,162 | -274,903 |